Trial Profile

Phase III trial of abuse-resistant oxycodone [Remoxy; Pain Therapeutics] in patients with moderate to severe osteoarthritis pain.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxycodone (Primary)
Indications Musculoskeletal pain; Osteoarthritis
Focus Registrational; Therapeutic Use
Sponsors Cassava Sciences; King Pharmaceuticals; Pain Therapeutics

Most Recent Events

20 Aug 2008 Results presented at 12th World Congress of the International Association for the Study of Pain (IASP) in August 2008.
07 Dec 2007 Status changed from in progress to completed.
06 Dec 2007 Preliminary data available; primary endpoint achieved. Pain Therapeutics expect to file a New Drug Application to the US FDA in the second quarter of 2008, based on the results of this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com